Archived: 9th Winter Conference
on Medicinal & Bioorganic Chemistry

January 25th - 29th 2009

Steamboat Springs Resort, Colorado


Sunday, January 25th 2009

Synthesis of Complex Molecules: from Natural Products to Pharmaceutical Scale Up

Program Chair: Tony Barrett, Imperial College

Viresh Rawal University of Chicago

Mycalamides, Pederin and Related Natural Products: Chemical Synthesis and Biological Studies

David Entwistle Pfizer

Process Development and Multi Kilogram Synthesis of Inhaled UK-432,097

Sheng Cui Amgen

Practical Asymmetric Conjugate Alkynylation of Meldrum’s Acid Derived Acceptors

Roberty Williams Colorado State University

HDAC Inhibitors

Monday, January 26th 2009

PK/PD Modeling and Simulation: Opportunities to bridge the Drug Discovery to Drug Development Divide

Program Chair: Dennis Dean, Merck Research Laboratories

Greg Winchell Merck

PK/PD Modeling and Simulation – Fundamentals and Applications to Drug Development

Maury Emery Amgen

PK/PD Modeling in Candidate Selection and Early Development

Michael Klimas Merck

Application of Imaging in Translational Drug Discovery and Development

William Kielbasa Lilly

An Animal to Human Translational PK-PD Approach Based on Brain Receptor Occupancy To Establish Clinical Dose

Novel Approaches for the Pharmacological Treatment of Pain

Program Chair: Philippe Nantermet, Merck Research Laboratories

Darrell Henze Merck

Overview of the Field, Challenges and Opportunities

Doug Johnson Pfizer

US FAAH Inhibitors for the Treatment of Pain

Peter Petillo Deciphera Pharmaceuticals

Molecular Mechanisms of Acquired Resistance to Kinase Inhibitors

Puwen Zhang Wyeth

Synthesis and Activity of 1-(3-amino-2-hydroxy-1-phenylpropyl)Indolin-2-ones and Derivatives: Discovery of Selective Norepinephrine Reuptake Inhibitor WAY-318068

Craig Stump Merck

CGRP Receptor Antagonists as Novel Pain Therapeutics

Tuesday, January 27th 2009

The University of Kansas Department of Medicinal Chemistry

Program Chair: Jeff Aube, University of Kansas

Jane Aldrich University of Kansas

Identification of a Systemically Active Peptidic Kappa Opioid Receptor Antagonist and its Potential Applications

Brian Blagg University of Kansas

Old Drugs for New Targets: A Case Study with Novobiocin and Hsp90

Blake Peterson University of Kansas

Synthetic Mimics of Mammalian Cell Surface Receptors: New Tools for Drug Delivery and Probes of Cellular Biology

Tom Prisinzano University of Kansas

Utilizing Nature as a Source of New Probes for CNS Disorders

Oral Session I

Program Chair: Mike VanNieuwenhze, Indiana University

Sebastian Kroll Imperial College

Towards the Synthesis of Selective CDK7 Inhibitors as Potential Anti-Cancer Drugs

Peter G. Ruminski Pfizer

Design of Orally Active and Highly Specific Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis

Aiming Sun Ph.D Emory University

Discovery of Potent Measles Virus RNA-Dependent RNA Polymerase Inhibitors

Alexander Khvat ChemDiv

Discovery of Developmental Pathway Inhibitors: A Case Study for Hedgehog Pathway Modulators

Scott Webster University of Edinburgh

The Discovery of Novel Inhibitors of 11b-Hydroxysteroid Dehydrogenase Type 1 (11b-HSD1)

Mike Shultz Novartis Institutes for Biomedical Research

Hydroxamate Based Histone Deacetylase Inhibitors with Improved Potency and Reduced Affinity for the hERG Ion Channel

Wednesday, January 28th 2009

Recent Advances in Understanding and Overcoming Drug Resistance

Program Chair: Daniel Flynn, Deciphera Pharmaceuticals

Thomas O'Hare Oregon Health Sciences University

Predicting and Controlling BCR-ABL Mutation-Mediated Resistance in CML: Cornering an Escape Artist

Tomasz Skorski Temple

Oncogenic Tyrosine Kinases Modulate Genomic Stability and Apoptosis to Resist Their inhibitors and Promote Malignant Disease Progression

Gerry Wright McMaster University

New Mechanisms of Antibiotic Resistance, and Reversing Resistance with Small Molecules

Shahriar Mobashery

Notre Dame Resistance to beta-Lactam Antibiotics in Methicillin-Resistant Staphylococcus Aureus (MRSA)

Poster Session

Program Chair: Jack Hodges, Berry & Associates

Mr. Werner & Steven V. Ley University of Cambridge

Not Itemized

Thursday, January 29th 2009

Oral Session II

Program Chair: Mike Rafferty, Deciphera Pharmaceuticals

Jim Monn Eli Lilly

Glutamate Receptor Agonist/Antagonists

Christopher Schneider University of Minnesota

Total Synthesis and Analog Development of Oximidine II: Discovery of an Unprecedented Reductive Castro-Stephens Tandem Reaction

Frank Schoenen University of Kansas

Modular Approach to Compound Libraries Inspired by Martinellic Acid and the Steroid Nuclear Hormones

Jeroen Verheijen Wyeth Research

Pyrazolopyrimidines as ATP Competitive, Highly Potent and Selective MTOR Inhibitors for Oncology

Anthony Lozama University of Kansas

Novel Opioid Receptor Probes Derived From Structural Modification to the Neo-Clerodane Diterpene

Media Sponsors